Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Sf3b1+/K700E hematopoietic stem cells create their own expansion niche

Elodie Henriet, LaShanale Wallace, John Harper et al. Nov 03, 2025 pp. 861-861 10.1182/blood-2025-861

Abstract Myelodysplastic syndromes (MDS) is an heterogenous group of clonal hematopoietic disorders that affect older individuals. It is cha...

Safety and feasibility of outpatient myeloablative total marrow and lymphoid Irradiation–based allogeneic transplantation in adults with high-risk acute lymphoblastic leukemia

Alexia E. Gonzalez-Lozano, Gerardo Garcia-Salas, Miguel Campos et al. Nov 03, 2025 pp. 6000-6000 10.1182/blood-2025-6000

Abstract Background Myeloablative total body irradiation (TBI) has long been a fundamental part of conditioning regimens...

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes

Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori et al. Nov 03, 2025 pp. 4782-4782 10.1182/blood-2025-4782

Abstract Introduction: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder character...

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia

David Kuter, Chen Yunfei, Nicola Cooper et al. Nov 03, 2025 pp. 3049-3049 10.1182/blood-2025-3049

Abstract Background and significance: Immune thrombocytopenia (ITP) is a rare autoimmune bleeding disorder characterized by severe thrombocy...

Association of delayed platelet recovery and lower nadir counts with adverse outcomes in heparin-induced thrombocytopenia

Aamna Khan, Hannah Mahjoub, Howard Chang et al. Nov 03, 2025 pp. 3115-3115 10.1182/blood-2025-3115

Abstract Introduction: Heparin-induced thrombocytopenia (HIT) is a rare, life-threatening prothrombotic disorder triggered by exposure to he...

Impact of chronic pain on acute pain trajectories in sickle cell disease: Insights from the sickle cell disease treatment with arginine therapy (STArT) randomized controlled trial

Nitya Bakshi, Derek Meyer, Jonathan Race et al. Nov 03, 2025 pp. 6524-6524 10.1182/blood-2025-6524

Abstract Background/Methods: STArT (NCT04839354) was a phase-3 double-blind, randomized placebo-controlled trial of intravenous (IV) arginin...

Single-cell RNA-sequencing of cerebrospinal fluid reveals transcriptional divergence of leukemia cells from bone marrow in pediatric B-ALL

Samuel Wong, Crystal Wang, Kara Davis et al. Nov 03, 2025 pp. 3360-3360 10.1182/blood-2025-3360

Abstract Central nervous system (CNS) relapse of B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, is associate...

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Michael Durante, J Christine Ye, Jens Hillengass et al. Nov 03, 2025 pp. 5763-5763 10.1182/blood-2025-5763

Abstract Introduction: Cytogenetic abnormalities such as del(17p), t(4;14), and gain(1q), among others and particularly when co-occurring, a...

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

Ziyu Wen, Xuan Zhou, Bingyu Lin et al. Nov 03, 2025 pp. 7358-7358 10.1182/blood-2025-7358

Abstract Background Myeloproliferative neoplasms during pregnancy increase the risk of maternal complications (including...

Metabolomic dynamics of cytokine release syndrome in CD19 CAR-T therapy

Zhouning Lin, Tingting Yang, Mingming Zhang et al. Nov 03, 2025 pp. 7663-7663 10.1182/blood-2025-7663

Abstract Purpose: Cytokine release syndrome (CRS) after CD19 CAR-T therapy poses a significant risk of morbidity and stands as a formidable...

The variable splicing factor RBM17 regulates MDS cell proliferation through H3K27la

Zhihong Wang, Yiting Lai, Zengbin Wang et al. Nov 03, 2025 pp. 2063-2063 10.1182/blood-2025-2063

Abstract Myelodysplastic syndrome is characterized by reduced production of all three lineages of blood cells, primarily affecting elderly i...

ICAM-2 mediates adhesion of acute myeloid leukemia cells to bone marrow microenvironment and promotes chemoresistance

Xinqi Li, Muheremu Muhetaer, Jin xian Liu et al. Nov 03, 2025 pp. 1691-1691 10.1182/blood-2025-1691

Abstract Abstract Introduction: Relapse and drug resistance of acute myeloid leukemia (AML) are the main challenges in clinical treatment, a...

Early and safe administration of G-CSF in AML patients treated with venetoclax-based therpy: Clinical and molecular insights from a single czech center

Lubomir Minarik, Zuzana Zemanova, Tomas Stopka et al. Nov 03, 2025 pp. 6906-6906 10.1182/blood-2025-6906

Abstract Introduction: This analysis evaluates the impact of early administration of the growth factor G-CSF during the...

Remodeling the bone marrow tumor microenvironment with CART cell therapy to overcome resistance in multiple myeloma

Jennifer Feigin, Omar Gutierrez Ruiz, Carli Stewart et al. Nov 03, 2025 pp. 1028-1028 10.1182/blood-2025-1028

Abstract B cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CART) cell therapies have emerged as a potentially curative...

Procedure-triggered late-onset congenital thrombotic thrombocytopenic purpura: Unmasking functional impact of a heterozygous synonymous ADAMTS13 variant (c.1716G>A) associated with reduced enzyme expression

Arvin Akhavan, Sharareh Tafakori, Sravya Gundapaneni et al. Nov 03, 2025 pp. 4881-4881 10.1182/blood-2025-4881

Abstract Background: Congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw–Schulman syndrome, is a...

A large language model-based framework for automated phenotypic characterization in myeloproliferative neoplasms

Muhammad Ali Khan, Salman Ayub Jajja, Japneet Kaur Oberoi et al. Nov 03, 2025 pp. 5605-5605 10.1182/blood-2025-5605

Abstract Background Accurate diagnosis and risk stratification in myeloproliferative neoplasms (MPNs) rely on expert interpretation of compl...

CRE intestinal colonization correlates with increased progression risk following CAR T cell therapy in relapsed/refractory lymphoma

Qing Yin, Yaxian Ma, Zetong Hong et al. Nov 03, 2025 pp. 1939-1939 10.1182/blood-2025-1939

Abstract Introduction The rate of carbapenem-resistant Enterobacteriaceae (CRE) detection in hematology-oncology units h...

Longitudinal immune reconstitution dynamics in refractory T-ALL treated with CD7 CAR-T cells bridging to allogeneic stem cell transplantation

Guo-Ling Wang, Han-Peng Luo, Ting Wang et al. Nov 03, 2025 pp. 3325-3325 10.1182/blood-2025-3325

Abstract Introduction T-cell acute lymphoblastic leukemia (T-ALL) is associated with a poor prognosis, with 20–30% of ad...

Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples

J Wiedmeier-Nutor, Mariano Arribas, Karl Franke et al. Nov 03, 2025 pp. 4020-4020 10.1182/blood-2025-4020

Abstract Background: Minimal residual disease (MRD) is a critical prognostic and therapeutic response marker in multiple myeloma (MM). Two ma...

Lessons learned from the clinical trial portfolio of ixazomib in multiple myeloma: A systematic review and meta-analysis

Darshi Shah, Veer Shah, Karan Shah et al. Nov 03, 2025 pp. 6199-6199 10.1182/blood-2025-6199

Abstract Introduction: Ixazomib is a next-in-class oral proteasome inhibitor approved for relapsed multiple myeloma (MM). However, it has fa...

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Francisco Rodolfo Saenz, Bouthaina Dabaja, Naval Daver et al. Nov 03, 2025 pp. 1727-1727 10.1182/blood-2025-1727

Abstract Introduction: Immune checkpoint inhibitors have been relatively ineffective in acute myeloid leukemias (AML), likely due to immune...

Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections

Haris Sohail, Lindsay Wilson, Jennifer Collins et al. Nov 03, 2025 pp. 5-5 10.1182/blood-2025-5

Abstract Background The use of intravenous (IV) iron for treating iron deficiency anemia during acute infections remains...

Piezo1 is essential for endothelial-to-hematopoietic transition and hematopoietic stem/progenitor cell generation during embryonic development

Shuwen Wang, Xiaoyu Zhang, Jun Peng Nov 03, 2025 pp. 1376-1376 10.1182/blood-2025-1376

Abstract Introduction Hematopoietic stem cells (HSCs) form the basis of the hematopoietic system, with essential functions including long-te...

Molecular distinctiveness of duodenal-type follicular lymphoma revealed by integrated multi-omic analysis

Hisashi Hashimoto, Suguru Fukuhara, Akiko Miyagi Maeshima et al. Nov 03, 2025 pp. 3524-3524 10.1182/blood-2025-3524

Abstract Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma, typically presenting with widespread nodal involv...

Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience

Mariana Kerbauy, Danielle Ovigli, Newton Centurião et al. Nov 03, 2025 pp. 7607-7607 10.1182/blood-2025-7607

Abstract Background: Teclistamab is a B-cell maturation antigen (BCMA)-targeting bispecific T-cell engager approved for commercialization in...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page